Home / Health / Breakthrough: 77% See Lupus Improvement with Gazvya
Breakthrough: 77% See Lupus Improvement with Gazvya
10 Mar
Summary
- An IV drug, obinutuzumab, significantly reduced lupus symptoms in a new trial.
- 77% of patients on the drug saw major symptom improvement after one year.
- The drug nearly doubled remission rates compared to placebo.
A new clinical trial has demonstrated that the already-approved IV drug obinutuzumab, marketed as Gazvya, dramatically lessens lupus symptoms. Researchers reported on March 6, 2026, that over three-quarters of lupus patients treated with Gazvya experienced significant symptom improvement after a year. This marks a substantial advancement in managing systemic lupus erythematosus (SLE).
The study, published in The New England Journal of Medicine, found that Gazvya not only improved symptom reduction but also extended the time between lupus flares. The remission rate nearly doubled compared to patients receiving a placebo, with 35% of Gazvya recipients achieving remission versus 14% in the placebo group.
Gazvya functions by prompting the immune system to eliminate B-cells, the producers of antibodies that attack the body in autoimmune diseases like lupus. While the drug showed promising efficacy, patients on Gazvya experienced a slightly higher rate of serious side effects, including pneumonia and infections.
Lead researcher Dr. Richard Furie highlighted the potential for robust disease control with reduced steroid reliance, a significant benefit for patients. Levi Garraway, chief medical officer for the Roche Group, which makes Gazvya, expressed optimism about bringing this treatment to more patients worldwide.
